Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Newtonoid is a biotechnology company based in Ann Arbor, Michigan, focused on developing magnetic nanoparticle-mediated hyperthermia (MNH) for the treatment of solid tumors. Founded by Dr. James R. Baker Jr., a pioneer in nanotechnology, the company utilizes a proprietary platform that employs external magnetic fields to excite nanoparticles localized within tumors, generating therapeutic heat to destroy malignant cells. This localized thermal ablation technique is designed to be highly targeted, minimizing damage to surrounding healthy tissue while offering a potentially safer alternative or adjunct to conventional oncology treatments. Currently in the pre-clinical stage, Newtonoid's technology represents a specialized application of interventional oncology aimed at improving outcomes for patients with difficult-to-treat cancers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Newtonoid.